Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of cns activity with isovaleramide, isovaleric acid, or a related compound

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Coumpounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides

Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological diseases or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacologic half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid

Compounds Active at a Novel Site on Receptor-operated Calcium Channels Useful for Treatment of Neurological Disorders and Diseases

Compounds active at a novel site on receptor-operated calciu m channels useful for treatment of neurological disorders

Treatment of spasticity, convulsions by isovaleric acid derivatives cns depressants

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid

Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same

A method of treating a neurologic or neuropsychiatric disorder or disease in a mammal is provided. The method comprises administering a fatty acid amide hydrolase inhibitor in an amount sufficient to inhibit deamidation of a fatty acid amide. A method of identifying a fatty acid amide hydrolase inhibitor useful in the treatment of a neurologic or neuropsychiatric disorder is also provided. A method of identifying a fatty acid amide or fatty acid useful in the treatment of a neurologic or neuropsychiatric disorder is also provided.

Anticonvulsant and central nervous system-active bis(fluorophenyl)alkylamides, corresponding acids, and uses

Bis(Fluorophenyl)alkylamides have been chemically synthesized which possess beneficial pharmacological properties (e.g., anticonvulsant activity) useful for the treatment of neurological disease or disorders, such as, for example, epilepsy, convulsions, and seizure disorders. The preferred compounds of the invention also cause little sedation and have high therapeutic and protective indices in animal models of epilepsy. These compounds further possess long pharmacologic half-lives, which, in practical clinical therapeutic application, should translate into once-a-day dosing, of great benefit to patients suffering from these diseases and/or disorders. These compounds may also be of further clinical utility in the treatment of other diseases and disorders of the central and peripheral nervous systems, or diseases or disorders affected by them, including, but not limited to, spasticity, skeletal muscle spasms and pain, restless leg syndrome, anxiety and stress, and bipolar disorder.

Treatment of spasticity, convulsions by isovaleric acid derivatives cns depressants

Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and its pharmaceutically acceptable salts, esters, and substituted amides, exhibit clinically significant pharmacological properties which implicate a treatment for a variety of pathological conditions, including spasticity and convulsions, which are ameliorated by effecting a mild depression of CNS activity. The compositions in question generally are non-cytotoxic and do not elicit weakness or sedative activity at doses that are effective for the symptomatic treatment of such pathological conditions.

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amyotrophic lateral sclerosis (ALS).

Methods and compounds for treating neurologic or neuropsychiatric disorders and identifying compounds to treat the same

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Method for identifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compounds is active on a receptoroperated calcium channel, including but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.

Treatment of spasticity, convulsions by isovalericacid derivatives cns depressants.

Treating a variety of pathological conditions, including spasticity and convulsions, by effecting modulation of cns activity with isovaleramide, isovaleric acid, or a related compound

Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and certain structurally related compounds exhibit clinically significant pharmacological properties which implicate a treatment for a variety of pathological conditions, including spasticity and convulsions, which are ameliorated by effecting a modulation of CNS activity. The compositions in question generally are non-cytotoxic and do not elicit weakness or sedative activity at doses that are effective for the symptomati c treatment of such pathological conditions.

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders and diseases

Method for indentifying a compound useful for the therapeutic treatment of a neurological disease or disorder such as stroke, head trauma, spinal cord injury, epilepsy, anxiety, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease or Parkinson's Disease, or useful as a muscle relaxant, analgesic, or adjuvant to general anesthetics. The compounds is active on a receptor-operated calcium channel, including, but not limited to, that present as part of an NMDA receptor-ionophore complex, a calcium-permeable AMPA receptor, or a nicotinic cholinergic receptor, as a noncompetitive antagonist. The method includes identifying a compound which binds to the receptor-operated calcium channel at the site bound by the arylalkylamines Compound 1, Compound 2 or Compound 3.

Compounds active at a novel site on receptor-operated calcium channels useful for treatment of neurological disorders

Method and compositions for treating a patient having a neurological disease or disorder, such as stroke, head trauma, spinal cord injury, spinal cord ischemia, ischemia- or hypoxia-induced nerve cell damage, epilepsy, anxiety, neuropsychiatric or cognitive deficits due to ischemia or hypoxia such as those that frequency occur as a consequence of cardiac surgery under cardiopulmonary bypass, or neurodegenerative diseases such as Alzheimer's Disease, Huntington's Disease, Parkinson's Disease, or amytrophic lateral sclerosis (ALS).

ACTIVE COMPOUNDS IN NEW SITES OF CALCIUM CHANNELS ACTIVATED BY USEFUL RECEIVERS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS.

SE DESCRIBE UN PROCEDIMIENTO Y COMPOSICIONES PARA TRATAR UN PACIENTE QUE PRESENTA UNA ENFERMEDAD O TRASTORNOS NEUROLOGICOS, TALES COMO ACCIDENTES CEREBROVASCULARES, TRAUMATISMOS CEFALICOS, LESIONES EN LA MEDULA ESPINAL, ISQUEMIA DE LA MEDULA ESPINAL, LESIONES EN LAS CELULAS NERVIOSAS INDUCIDAS POR ISQUEMIA O POR HIPOXIA, EPILEPSIA, ANSIEDAD, DEFICIENCIAS NEUROPSIQUIATRICAS O COGNITIVAS DEBIDAS A ISQUEMIA O HIPOXIA TALES COMO LAS QUE SE PRODUCEN CON FRECUENCIA COMO CONSECUENCIA DE CIRUGIA CARDIACA BAJO BYPASS CARDIOPULMONAR, O ENFERMEDADES NEURODEGENERATIVAS TALES COMO LA ENFERMEDAD DE ALZHEIMER, LA ENFERMEDAD DE HUNTINGTON, LA ENFERMEDAD DE PARKINSON O LA ESCLEROSIS LATERAL AMIOTROFICA (ALS). A PROCEDURE AND COMPOSITIONS ARE DESCRIBED TO TREAT A PATIENT THAT PRESENTS A DISEASE OR NEUROLOGICAL DISORDERS, SUCH AS CEREBROVASCULAR ACCIDENTS, CEPHAL TRAUMATISMS, SPINAL MEDULA INJURY, ISSUEMS, NESCASUESDIA, DIVESTRIAL DISEASE, NON-CELLS EPILEPSY, ANXIETY, NEUROPSYCHIATRIC OR COGNITIVE DEFICIENCIES DUE TO ISCHEMIA OR HYPOXIA SUCH AS THOSE THAT ARE FREQUENTLY CAUSED AS A CONSEQUENCE OF CARDIAC SURGERY BY CARDIOPULMONARY BYPASS, OR NEURODEGERMALITY DISEASE INTO HERMANERMALITY INTOFORMALITY INTO HERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMERMENTERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY IN ORERMINITY FERMERMENTITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY INTO HERMANERMALITY IN HERMERMANITY PERMITS AMIOTROPHIC LATERAL SCLEROSIS (ALS).

Treatment of spasticity, convulsions by isovaleric acid derivatives cns depressants

Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and its pharmaceutically acceptable salts, esters, and substituted amides, exhibit clinically significant pharmacological properties which implicate a treatment for a variety of pathological conditions, including spasticity and convulsions, which are ameliorated by effecting a mild depression of CNS activity. The compositions in question generally are non-cytotoxic and do not elicit weakness or sedative activity at doses that are effective for the symptomatic treatment of such pathological conditions.

Verbindungen, die an eine neue stelle auf rezeptor - funktionierenden kalziumkanalwirksam sind, zur behandlung von neurologischen erkrankungen

Antikonvulsive und zns-aktive bis-fluoralkylamide

Compuestos activos en un sitio novedoso en canales de calcio operados por receptor utiles para el tratamiento de trastornos neurologicos.

Método de composiciones para tratar un paciente que tiene un trastorno o enfermedad neurologica, tal como un ataque, trauma de cabeza, lesion en la médula espinal, isquemia o hipoxia, epilepsia, ansiedad, déficits neuropsiquiátricos o cognitivos debidos a la isquemia o hipoxia tales como aquellos que ocurren frecuentemente como una consecuencia de la cirugía cardíaca bajo derivacion cardiopulmonar o enfermedades neurodegenerativas tales como enfermedad de Alzheimer, enfermedad de Huntington, enfermedad de Parkinson o esclerosis lateral amiotropica (ALS).

Zusammensetzungen enthaltend isovalerianamide zusammen mit ibuprofen

Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid

Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and its pharmaceutically acceptable salts, esters, and substituted amides, and other valerian-related compounds, in combination with NSAIDs exhibit clinically significant pharmacological properties which implicate a treatment for acute muscular aches, strains, and sprains which occur from a localized, external insult to a particular muscle or muscle group outside of, or peripheral to, the CNS. The compositions in question generally are non-cytotoxic and do not elicit weakness or sedative activity at doses that are effective for the symptomatic treatment of such pathological conditions.

Compositions comprising valerian extracts, isovaleric acid or derivatives thereof with a nsaid

Preparations and extracts of valerian, as well as isovaleramide, isovaleric acid, and its pharmaceutically acceptable salts, esters, and substituted amides, and other valerian-related compounds, in combination with NSAIDs exhibit clinically significant pharmacological properties which implicate a treatment for acute muscular aches, strains, and sprains which occur from a localized, external insult to a particular muscle or muscle group outside of, or peripheral to, the CNS. The compositions in question generally are non-cytotoxic and do not elicit weakness or sedative activity at doses that are effective for the symptomatic treatment of such pathological conditions.

Verbindungen, die an einer neuen stelle auf rezeptor-stimulierten kalziumkanälen wirksam sind,verwendbar zur behandlung von neurologischen krankheiten

Migraine treatments including isovaleramide compounds and serotonin agonists

A method of treating a migraine headache comprising administering at least one serotonin agonist and isovaleramide, .alpha.-methyl isovaleramide, or mixtures thereof to a patient suffering from a migraine. The at least one serotonin agonist is selected from the group consisting of sumatriptan, eleptriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, ergotamine, an ergotamine derivative, and mixtures thereof. A migraine treatment is also provided.

Migraine treatments including isovaleramide compounds and serotonin agonists

A method of treating a migraine headache comprising administering at least one serotonin agonist and isovaleramide, α-methyl isovaleramide, or mixtures thereof to a patient suffering from a migraine. The at least one serotonin agonist is selected from the group consisting of sumatriptan, eleptriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, ergotamine, an ergotamine derivative, and mixtures thereof. A migraine treatment is also provided.

Migraine treatments including isovaleramide compounds and serotonin agonists

A method of treating a migraine headache comprising administering at least one serotonin agonist and isovaleramide, α-methyl isovaleramide, or mixtures thereof to a patient suffering from a migraine. The at least one serotonin agonist is selected from the group consisting of sumatriptan, eleptriptan, naratriptan, rizatriptan, zolmitriptan, almotriptan, frovatriptan, ergotamine, an ergotamine derivative, and mixtures thereof. A migraine treatment is also provided.